| 2026-05-14 08:45 |
8-K |
|
merger agreement |
0.98
|
Completed merger: Biogen acquired Apellis for $41/share cash plus CVR; tender offer accepted 82.4% shares, merger effective May 14, 2026. |
SEC · detail |
| 2026-05-14 07:53 |
SC TO-T |
|
tender offer |
1.00
|
Biogen completed acquisition of Apellis via tender offer at $41/share plus CVR, 82.4% tendered, merger effective May 14, 2026. |
SEC · detail |
| 2026-05-14 07:46 |
SC 14D9 |
|
tender offer |
1.00
|
Biogen tender offer for Apellis completed; 82.4% acceptance; merger closing imminent under DGCL 251(h). |
SEC · detail |
| 2026-05-12 07:06 |
SC TO-T |
|
tender offer |
0.98
|
Biogen's tender offer for Apellis at $41/share plus CVR; HSR approval obtained, regulatory condition satisfied. |
SEC · detail |
| 2026-05-12 07:00 |
SC 14D9 |
|
tender offer |
0.98
|
Biogen's tender offer for Apellis at $41/share plus CVRs; HSR clearance obtained, merger imminent. |
SEC · detail |
| 2026-05-06 16:37 |
SC TO-T |
|
tender offer |
0.98
|
Biogen's third-party tender offer for Apellis at $41/share plus CVR, Amendment No. 1 filed mid-transaction. |
SEC · detail |
| 2026-05-06 16:30 |
SC 14D9 |
|
tender offer |
0.98
|
Biogen's tender offer for Apellis at $41/share plus CVR, with SC 14D-9/A amendment addressing stockholder litigation. |
SEC · detail |
| 2026-05-04 07:05 |
8-K |
["5.02"] |
merger agreement |
0.98
|
Apellis amending separation benefits plan in connection with Biogen merger agreement closing. |
SEC · detail |